IXICO PLC (AIM:IXI, OTC:PHYOF)'s (IXICO PLC (AIM:IXI, OTC:PHYOF)) chief business officer Lammert Albers talks to Proactive London's Katie Pilbeam about being chosen by its largest pharma client to provide neuroimaging services for a new phase III clinical trial into demyelinating disorder.
As Albers explains, trial will be conducted across 100 sites in 10 countries and is worth more than £1.0mln over seven years.
This is the second phase III trial in this disease area that IXICO has secured in the last 12 months.